-- Hangzhou Jiuyuan Genetic Biopharmaceutical (HKG:2566) obtained clinical trial approval for the JY54 Injection from China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.
The product is intended to contribute to glycemic control and weight management.